Peng Wei

Peng Wei

Auto-generated profile, based on publicly available information

Peng Wei

Center for Nanomedicine and Theranostics, Department of Chemistry, Technical University of Denmark, Kongens Lyngby, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2020 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
JHJun Hu
Jun Hu
WWWenrui Wu
Wenrui Wu
YQYufei Qin
Yufei Qin
CLChao Liu
Chao Liu
PWPeng Wei
Peng Wei
JYJian Yin
Jian Yin

12 October 2018 in Chemistry – An Asian Journal
Verified
Journal Article
Closed access
PDF file
JHJing Hu
Jing Hu
PWPeng Wei
Peng Wei
PSPeter H. Seeberger
Peter H. Seeberger
JYJian Yin
Jian Yin

1 August 2020 in Colloids and Surfaces A: Physicochemical and Engineering Aspects
Verified
Journal Article
Closed access
PWPeng Wei
Peng Wei
ZYZhou Ye
Zhou Ye
SCShuya Cao
Shuya Cao
SBShuo Bai
Shuo Bai
PSPeter H. Seeberger
Peter H. Seeberger
JHJing Hu
Jing Hu

21 June 2024 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
CRCecilia Romanò
Cecilia Romanò
HJHao Jiang
Hao Jiang
STSahar Tahvili
Sahar Tahvili
PWPeng Wei
Peng Wei
UKUlrik B. Keiding
Ulrik B. Keiding
MCMads Clausen
Mads Clausen
INKT cells – often referred to as the “Swiss Army knife” of the immune system – have emerged as central players in cancer vaccine therapies.

17 September 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
PWPeng Wei
Peng Wei
CRCecilia Romanò
Cecilia Romanò
CLChengxin Li
Chengxin Li
GCGael Clergeaud
Gael Clergeaud
TAThomas L. Andresen
Thomas L. Andresen
MCMads Clausen
Mads Clausen
Diseases caused by S. pneumoniae are the leading cause of child mortality. As antibiotic resistance of S. pneumoniae is rising, vaccination remains the most recommended solution. However, the existing pneumococcal polysaccharides vaccine (Pneumovax® 23) proved only to induce T-independent immunity, and strict cold chain dependence of the protein conjugate vaccine impedes its promotion in developing countries, where infections are most problematic. Affordable and efficient vaccines against pneumococcus are therefore in high demand. Here, we present an intranasal vaccine Lipo+CPS12F&αGC, containing the capsular polysaccharides of S. pneumoniae 12F and the iNKT agonist α-galactosylceramide in cationic liposomes. In BALB/cJRj mice, the vaccine effectively activates iNKT cells and promotes B cells maturation, stimulates affinity-matured IgA and IgG production in both the respiratory tract and systemic blood, and displays sufficient protection both in vivo and in vitro. The designed vaccine is a promising, cost-effective solution against pneumococcus, which can be expanded to cover more serotypes and pathogens.